Racial differences in scleroderma among women in Michigan
Corresponding Author
Timothy J. Laing MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
University of Michigan Medical Center, Division of Rheumatology, 3918 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109—0358Search for more papers by this authorBrenda W. Gillespie PhD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorMary B. Toth MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorMaureen D. Mayes MD, MPH
Wayne State University, Detroit, Michigan
Search for more papers by this authorRobert H. Gallavan Jr. PhD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorCarol J. Burns PhD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorJewel R. Johanns MS
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorBrenda C. Cooper MS
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorBrian J. Keroack MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorMary Chester M. Wasko MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorJames V. Lacey Jr. MPH
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorDavid Schottenfeld MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorCorresponding Author
Timothy J. Laing MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
University of Michigan Medical Center, Division of Rheumatology, 3918 Taubman Center, 1500 East Medical Center Drive, Ann Arbor, MI 48109—0358Search for more papers by this authorBrenda W. Gillespie PhD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorMary B. Toth MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorMaureen D. Mayes MD, MPH
Wayne State University, Detroit, Michigan
Search for more papers by this authorRobert H. Gallavan Jr. PhD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorCarol J. Burns PhD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorJewel R. Johanns MS
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorBrenda C. Cooper MS
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorBrian J. Keroack MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorMary Chester M. Wasko MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorJames V. Lacey Jr. MPH
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorDavid Schottenfeld MD
University of Michigan and the Multipurpose Arthritis and Musculoskeletal Disease Center, Ann Arbor
Search for more papers by this authorAbstract
Objective. To examine racial differences in disease onset, extent, manifestations, and survival among women with scleroderma.
Methods. A retrospective cohort study of women with scleroderma, diagnosed in Michigan between 1980 and 1991, was conducted. Clinical, laboratory, and demographic data were abstracted from the patients' medical records.
Results. A total of 514 women with scleroderma were identified: 117 (23%) were black and 397 (77%) were white. Among black women, the mean age at diagnosis was lower (44.5 years versus 51.5 years; P < 0.001) and diffuse disease was more common (49.6% versus 24.9%; P < 0.001) than among white women. The overall incidence of scleroderma was 14.1 per million per year: 22.5 per million per year in black women versus 12.8 per million per year in white women (P < 0.001). Pericarditis (P = 0.009), pulmonary hypertension (P < 0.001), pleural effusions (P = 0.01), myositis (P = 0.02), and an erythrocyte sedimentation rate >40 mm/hour (P < 0.001) were more frequent among black women, while white women were more likely to have digital infarctions (P < 0.001). Survival at 7 years from diagnosis was 72.5% among black women and 77.6% among white women. Age-adjusted survival was significantly reduced among black women (P = 0.033), most likely because of increased diffuse involvement. Survival among those with renal or pulmonary involvement was also significantly reduced.
Conclusion. Black women with scleroderma were significantly more likely than white women to develop diffuse disease, be diagnosed at a younger age, have a higher incidence of inflammatory features, and have a worse age-adjusted survival rate.
References
- 1 Silman AJ, Hochberg MC: Scleroderma. In, Epidemiology of the Rheumatic Diseases. Edited by AJ Silman, MC Hochberg. Oxford, Oxford University Press, 1993
- 2 Medsger TA Jr, Steen VD: Classification, prognosis. In, Systemic Sclerosis. Edited by PJ Clements, DE Furst. Baltimore, Williams and Wilkins, 1996
- 3 Steen V, Conte C, Santoro D, Casterline GLZ, Oddis CV, Medsger TA Jr: Twenty-year incidence survey of systemic sclerosis (abstract). Arthritis Rheum 31 (Suppl 4): S57, 1988
- 4 Medsger TA Jr, Masi AT: Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med 74: 714–721, 1971
- 5 Hochberg MC, Lopez-Acuna D, Gittelsohn AM: Mortality from systemic sclerosis (scleroderma) in the United States, 1969–1977. In, Current Topics in Rheumatology. Systemic Sclerosis (Scleroderma). Edited by CM Black, AR Myers. New York, Gower Medical Publishing, 1985
- 6 Schottenfeld D, Burns CJ, Gillespie BW, Laing TJ, Mayes MD, Heeringa SG, Alcser KH: The design of a population-based case-control study of systemic sclerosis (scleroderma): commentary on the University of Michigan Study. J Clin Epidemiol 48: 583–586, 1995
- 7 Hook EB, Regal RR: Effect of variation in probability of ascertainment by source (variable catchability) upon capture-recapture estimates of prevalence. Am J Epidemiol 137: 1148–1166, 1993
- 8 Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee: Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23: 581–590, 1980
- 9 Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481, 1958
- 10 Hirschenberger W: The validity of death certificates among documented scleroderma cases in Metropolitan Detroit (thesis). Ann Arbor, University of Michigan School of Public Health, 1995
- 11 Office of the State Registrar and Center for Health Statistics: Michigan Health Statistics. Lansing, MI, Michigan Department of Public Health, 1993
- 12 Cox DR: Regression models and life tables (with discussion). J Royal Stat Soc B 74: 187–220, 1972
- 13 Lawless JF: Statistical Models and Methods for Lifetime Data. New York, John Wiley and Sons, 1982
- 14 Reveille JD, Durban E, Goldstein R, Moreda R, Arnett FC: Racial differences in the frequencies of scleroderma-related auto-antibodies. Arthritis Rheum 35: 216–218, 1992
- 15 Vayssairat M, Baudot N, Abuaf N, Johanet C: Long-term follow-up study of 164 patients with definite systemic sclerosis: classification considerations. Clin Rheumatol 11: 356–363, 1992
- 16 McNeilage LJ, Youngchaiyud U, Whittingham S: Racial differences in antinuclear antibody patterns and clinical manifestations of scleroderma. Arthritis Rheum 32: 54–60, 1989
- 17 Tan FK, Howard RF, Reveille JD, Moulds JM, Paxton G, Arnett FC: Case control study of systemic sclerosis among Choctaw native Americans in southeastern Oklahoma (abstract). Arthritis Rheum 37 (Suppl 9): S282, 1994
- 18 Tamaki T, Mori S, Takehara K: Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 283: 366–371, 1991
- 19 Barnett AJ: Scleroderma. In, Progressive Systemic Sclerosis. Edited by IN Kugelmass. Springfield, IL, Charles C. Thomas, 1974
- 20 Silman A, Jannini S, Symmons D, Bacon P: An epidemiological study of scleroderma in the West Midlands. Br J Rheumatol 27: 286–290, 1988
- 21 Michet CJ, McKenna CH, Elveback LR, Kaslow RA, Kurland LT: Epidemiology of systemic lupus erythematosus and other connective tissue disease in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 60: 105–113, 1985
- 22 Medsger TA Jr, Steen V: Systemic sclerosis and related syndromes: clinical features and treatments. In, Primer on the Rheumatic Diseases. Edited by HR Schumacher, JH Klippel, WJ Koopman. Atlanta, Arthritis Foundation, 1993
- 23 Seibold JR: Systemic sclerosis: clinic features. In, Rheumatology. Edited by JH Klippel, PA Dieppe. St. Louis, Mosby, 1994
- 24 Agresti A: Categorical Data Analysis. New York, John Wiley and Sons, 1990
- 25 Masi AT, D'Angelo WA: Epidemiology of fatal systemic sclerosis (diffuse scleroderma): a 15-year survey in Baltimore. Ann Intern Med 66: 870–883, 1967
- 26 Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H: Survival with systemic sclerosis (scleroderma): a life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med 75: 369–376, 1971
- 27 Medsger TA Jr, Masi AT: Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis 26: 647–660, 1973
- 28 Medsger TA Jr, Masi AT: The epidemiology of systemic sclerosis (scleroderma) among male U.S. veterans. J Chronic Dis 31: 73–85, 1978
- 29 Altman RD, Medsger TA Jr, Bloch DA, Michel BA: Predictors of survival in systemic sclerosis (scleroderma). Arthritis Rheum 34: 403–413, 1991
- 30 Bennett R, Bluestone R, Holt PLJ, Bywaters EGL: Survival in scleroderma. Ann Rheum Dis 30: 581–588, 1971
- 31
Farmer RG,
Gifford RW Jr,
Hines EA:
Prognostic significance of Raynaud's phenomenon and other clinical characteristics of systemic scleroderma: a study of 271 cases.
Circulation
XXI:
1088–1095,
1960
10.1161/01.CIR.21.6.1088 Google Scholar
- 32 Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S, Ramsden M, Rosenbach TO, Sukenik S, Wilkinson S, Keyston EC: Mortality in systemic sclerosis (scleroderma). QJM 82: 139–148, 1992
- 33 Wynn J, Fineberg N, Matzer L, Cortada X, Armstrong W, Dillon JC, Kinney EL: Prediction of survival in progressive systemic sclerosis by multivariate analysis of clinical features. Am Heart J 110: 123–127, 1985
- 34 Sackner MA: Scleroderma. New York, Grune and Stratton, 1966